Jame Abraham: we need to have a better understanding of HER-2 ultra-low and how to define it
Jame Abraham shared on X:
“New approval for TDXd for metastatic breast cancer with HER – 2 low and ultra-low ( HER -2 IHC 2+ ) FISH -) IHC 1+, HER -2 – >0, <1 +-.
We need to have a better understanding of HER -2 ultra-low and how to define it!”
Read further.
Source: Jame Abraham/X
Jame Abraham, MD, FACP, is Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic and a Professor of Medicine at Cleveland Clinic Lerner College of Medicine. He also is a Deputy Editor at the ASCO Post and Journal of Oncology Practice of ASCO.
Dr. Abraham is a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee and holds leadership roles in NRG Oncology and the National Surgical Adjuvant Breast and Bowel Project (NSABP).
